Effect of omeprazole, rabeprazole, and rebamipide on the accuracy of urea breath test in patients with *Helicobacter pylori* infection

Duangporn Thong-Ngam, Maneerat Chayanupatkul, Thirada Thongbai

Department of Physiology, Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Background: The urea breath test (UBT) has been widely used for *H. pylori* eradication after treatment. The breath test could be adversely affected by various factors including proton pump inhibitors (PPIs) that are also used in the therapy for *H. pylori* infection. Objective: Determine the effect of omeprazole, rabeprazole and the mucoprotective agent rebamipide, on the UBT. Methods: Fifty-six patients with dyspepsia and positive for *H. pylori* by rapid urease test were enrolled. They were classified into three groups: Group 1 (n=25) received omeprazole 20 mg once daily, group 2 (n=13) received rabeprazole 20 mg once daily, and group 3 (n=18) received rebamipide 100 mg three times a day. All patients received a 14-day course of their medications. UBT was performed on day 0 as a baseline and on day 14 in all patients. In patients with negative results of UBT on day 14, the UBT was performed in consecutive weeks until the test became positive. Results: Fifty-six patients (20 men and 36 women) participated in the study. Their mean age was 46.77±14.3 years. False negative rate after 14-day treatment in omeprazole, rabeprazole and rebamipide group were 20.0%, 30.8%, and 0% respectively. There was a significant difference between 13C level in patients with negative and positive UBT results (2.7±0.7 vs. 22.9±3.7/mL, p=0.025). The reversal of false negative to true positive tests occurred within two weeks after discontinuation of omeprazole and rabeprazole. Conclusion: Proton pump inhibitors had an effect on the accuracy of *H. pylori* detection using UBT. Rabeprazole revealed a higher false negative rate in the UBT than omeprazole. The mucoprotective drug, rebamipide, did not influence negative results in the UBT.

Keywords: *Helicobacter pylori*, rabeprazole, rebamipide, urea breath test.

*Helicobacter pylori* infection is now considered the most common cause of peptic ulcer disease. It has been implicated as a major factor in the pathogenesis of gastric adenocarcinoma and low-grade gastric lymphoma of mucosa-associated lymphoid tissue (MALT) [1-3]. The detection of *H. pylori* can be done using several diagnostic tests. They include invasive tests, such as biopsy urease test, histology and culture, and non-invasive tests, such as serology, urea breath test and stool antigen test. These tests vary in sensitivity and specificity. The most commonly used diagnostic test in clinical practice in Thailand is the rapid urease test accomplished by mucosal biopsy during endoscopy with sensitivity of 88-95% and specificity of 95-100% [3]. The urea breath test (UBT) is also recommended for determination of success of *H. pylori* eradication. *H. pylori* causes urease splitting, which is uncommon in other important bacteria. Since the normal human stomach is devoid of urease, the detection of gastric urease is indicative of active *H. pylori* infection [3, 4]. Two UBTs are now approved by the US-FDA. One is a 13C based test and the other is a 14C based test. The both types of UBT are quite similar in sensitivity (90-96%) and specificity (88-98%) [3-15]. Despite its high accuracy, many factors...
have been implicated to cause false negative UBT including proton pump inhibitors (PPIs), H$_2$ receptor antagonists, bisphosphonates, and antibiotics.

PPIs have been widely used to manage acid-related disorders for the last decade. These agents selectively and irreversibly block the gastrin (H+/K$^+$-ATPase), a final step in acid secretion [5, 6]. They inhibit acid secretion independently of the state of parietal cell stimulation. PPIs are effective against gastroesophageal reflux disease (GERD), peptic ulcer, Barrett’s esophagus, Zollinger-Ellison syndrome. It is also a part of combination therapy for H. pylori eradication [5, 6]. PPIs comprise many agents that differ slightly in pharmacokinetics, potency, acid suppression, clinical efficacy, cost, and toxicity [5].

Previous studies have shown that taking PPIs could lead to false negative UBT with false negative rate. It ranges from 2.3% to 38.0% [7-11]. There were few studies regarding false negative rates with rabeprazole.

There are several hypotheses to explain the cause of false negative UBT tests. One concerns the effect of PPIs on intragastric pH by making the intragastric environment undesirable for H. pylori, leading to a fall in the bacterial load [12]. The rise in gastric pH caused by PPIs may reduce the utilization of urea into H. pylori, and thus bacterial urease activity [11]. PPIs also have a direct bactericidal effect against H. pylori, which in turn reduces the bacteria load [12-14]. In spite of abundant evidence supporting the adverse effect of PPIs on the sensitivity of UBT, it is still unclear whether rebamipide, a mucoprotective agent, could influence the accuracy of UBT. In the present study, we investigated the effect of omeprazole, rabeprazole, and rebamipide on the accuracy of the urea breath test.

**Materials and methods**

**Subject**

Fifty-six patients (20 men and 36 women) with dyspepsia attending the outpatient clinic at King Chulalongkorn Memorial Hospital were recruited in the study between January 2006 and December 2006. All patients enrolled in this study had undergone endoscopies with one biopsy at the antrum for the rapid urease test (CLO test®, Utah, USA), which had been read as H. pylori positive by changing from yellow to pink within 24 hours. Exclusion criteria consisted of previous gastric surgery, pregnancy, current breast feeding, gastric ulcer, duodenal ulcer, gastric cancer or known allergy to medications used in this study. The study was approved by the Ethics Committee of the Faculty of Medicine, Chulalongkorn University. Written informed consent was obtained from each patient prior to participation.

**Study design**

Fifty-six patients were randomly classified into three groups: omeprazole, rabeprazole, and rebamipide group. They were administered omeprazole 20 mg/day, rabeprazole 20 mg/day and rebamipide 300 mg/day, respectively. The UBT was performed twice, before starting medication and after 14-days of treatment. Patients in the omeprazole group were examined using $^{13}$C UBT, while the other two groups were tested using $^{14}$C UBT due to the availability of these tests. Breath tests were performed weekly after cessation of medication in patients with negative results of UBT on day 14 until the test became positive.

**Urea breath test**

Patients were requested not to take any medications that could influence the UBT results and come after an overnight fast. $^{13}$C UBT (Otsuka Pharmaceutical, Tokyo, Japan) was performed using molecular correlation spectroscopy (Continuous Real Time Breath ID System, Oridion, Jerusalem, Israel). After obtaining baseline breath samples, patients were requested to drink a solution of $^{13}$C urea 100 mg (Campo Scientific, Veenendaal, The Netherlands) in 50 mL of water. The second breath sample was taken 30 minutes later. The Breath ID continuously measures $^{13}$CO$_2$ and $^{12}$CO$_2$ concentrations from breath samples. We calculated the ratio of $^{13}$CO$_2$ to $^{12}$CO$_2$. The cut-off point for the Breath ID test has been determined to be four “delta over baseline” (DOB). A test result with DOB of equal (or greater than four) was defined as positive, whereas the final reading of DOB less than four was interpreted as negative.

$^{14}$C UBT was performed using PYtest kit with a microcount liquid scintillation counter (Kimberly-Clark/Ballard Medical Products, Roswell, USA). Six hours after fasting and two hours without smoking tobacco products, patients swallowed the capsule containing 1 μCi of $^{14}$C urea with 20 mL of lukewarm water, followed by an additional 20 mL of water three minutes later. At ten minutes post-dose, the patient was requested to take a deep breath, hold it for 3-10 seconds, and exhale through a straw into a mylar
breath collection balloon. Then, the air from the balloon was transferred into a scintillation vial containing hyamine, methanol and thymolphthalein. The patient continued breathing through to the system until discoloration occurred, indicating the adequacy of breath sample collection. Then, 10 mL scintillation fluid was added to each vial. The breath sample was analyzed for the presence of $^{14}$C with a liquid scintillation counter. The quantification was reported as disintegrations per minute (DPM). DPM less than 50 was considered negative, while DPM equal or greater than 200 was determined as positive.

**Statistical analysis**

Continuous data were expressed as mean ± SEM. Chi-square or Fisher’s exact test was used to compare the demographic characteristics and the number of false negative UBT among groups. Data processing was accomplished using SPSS software for windows (version 16, SPSS, Chicago, USA). All tests were considered significant at p < 0.05.

**Results**

Fifty-six patients (20 men and 36 women) participated in the study with a mean age of 46.8±14.3 years (range: 19-79 years). Patients enrolled in this study were classified into three groups. Twenty-five patients (8 men and 17 women) in the omeprazole group had average age of 46.0±2.8 years. The rabeprazole group was comprised of 13 patients (6 men and 7 women) with a mean age of 49.1±4.7 years. Another 18 patients (6 men and 12 women) were the rebamipide group with an average age of 46.2±3.1 years. There was no significant difference in the number of cases, ages and gender among groups. All demographic data in each group are shown in Table 1.

All patients with positive rapid urease test were confirmed to be positive by UBT on day 0. The 5/25 in the omeprazole group, 4/13 in the rabeprazole group and 0/18 in the rebamipide group had negative UBTs 14 days after treatment. These were considered as false negative because antibiotics for *H. pylori* eradication had not been prescribed. As shown in Table 1, percentage of false negative results in omeprazole, rabeprazole and rebamipide group were 20%, 30.8%, and 0%, respectively. The false negative rate in the rabeprazole group differed significantly from rebamipide group (p=0.023). Therefore, there was no significant difference in the false negative rate between rebamipide and omeprazole groups or between omeprazole and the rabeprazole group.

In the omeprazole group, the $^{13}$C level at baseline (mean±SEM: 25.52±3.29/mL) was higher than the $^{13}$C level 14 days after treatment (mean=18.77±3.38) without statistical significance. The $^{13}$C level in patients with negative results (mean±SEM: 2.68±0.7/mL) was found to be significantly lower than in those with positive tests (mean±SEM: 22.86±3.7 mL), p=0.025 (Fig. 1). The $^{13}$C level in omeprazole group did not seem to be influenced by sex, alcohol and smoking.

All patients with false negative results regained a positive test two weeks after drug cessation. No serious adverse effects were reported in all three groups.

**Table 1.** Demographic data and UBT test results in omeprazole, rabeprazole and rebamipide group.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Omeprazole</th>
<th>Rabeprazole</th>
<th>Rebamipide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>25</td>
<td>13</td>
<td>28</td>
</tr>
<tr>
<td>Age (years)</td>
<td>46.0±2.8</td>
<td>49.1±4.7</td>
<td>46.2±3.1</td>
</tr>
<tr>
<td>Gender (number, percent)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>17 (68%)</td>
<td>7 (54%)</td>
<td>12 (67%)</td>
</tr>
<tr>
<td>Male</td>
<td>8 (32%)</td>
<td>6 (46%)</td>
<td>6 (33%)</td>
</tr>
<tr>
<td>UBT result on day 14 (number, percent)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>20 (80%)</td>
<td>9 (69%)</td>
<td>18 (100%)</td>
</tr>
<tr>
<td>Negative</td>
<td>5 (20%)</td>
<td>4 (31%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>UBT result on day 21 (number, percent)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>5 (100%)</td>
<td>4 (100%)</td>
<td>-</td>
</tr>
</tbody>
</table>
The UBT was considered useful for initial diagnosis and for determining the success of Helicobacter pylori eradication [16]. In this study, patients in the omeprazole group were tested using 13C UBT, while the other two groups used 14C UBT due to the availability of these tests. The accuracy of the UBT could be affected by numerous factors including PPIs usage. Consequently, cessation of PPIs 7-14 days before performing UBT is recommended. This is, however, a critical issue for patients dependent on medications due to severe symptoms. In the present study, we determined the false negative rate associated with various types of PPIs. Since rebamipide though our numbers are relatively small, statistical analysis would require a larger patient population.

The percentage of false negative results was 20.0%, 30.8%, and 0% in the omeprazole, rabeprazole, and rebamipide group, respectively. A false negative rate caused by standard dose omeprazole differed among prior studies, ranging from 2.3% to 38.0% [7-11]. Levine A et al. [17] demonstrated that various types of PPIs had difference false negative rates ( pantoprazole 2.2%, omeprazole 4.1%, esomeprazole 13.6% and lansoprazole 16.6%). Similar results were also shown by Parente F et al. [10]. The reason for rabeprazole causing a high false negative rate could be explained by its potency and effect on H. pylori urease activity. Rabeprazole had faster onset of anti-secretory action and higher potency than omeprazole compared on 1 mg for mg basis [5]. In some studies, rabeprazole resulted in greater acid suppression than omeprazole [5-18]. In addition, growth inhibitory effect of rabeprazole over H. pylori was found to be more active than with omeprazole. As well, rabeprazole was about 10 times more potent than omeprazole in inhibiting urease at pH 5 in both cellular and cell-free systems in vitro [6]. Therefore, higher potency of rabeprazole in urease inhibition could lead to higher false negative rates in UBT compared with omeprazole.

Rebamipide, a gastroprotective agent widely used in Japan, acts through the stimulation of prostaglandin and mucus glycoprotein synthesis, exhibiting inhibitory effect on reactive oxygen species and inflammatory cytokines [19-21]. In this study, we determined whether a mucoprotective agent, such as rebamipide, could adversely affect the accuracy of UBT. In accordance with the study by Murakami K et al. [22], no false negative results were obtained in the rebamipide group. They also found that treatment with rebamipide did not affect the post-treatment UBT Δ13C% values. In the study by Adachi K et al. [23], no case gave a negative UBT result after rebamipide administration. Rebamipide did not affect the result of UBT, probably because it had no anti-secretory or anti-urease activity [24]. This positive effect of rebamipide might be beneficial in clinical practice. Since rebamipide might not have an effect on UBT, it could be used as an alternative drug for symptom relief in patients dependent on PPIs who have to stop medications before employing the UBT.
All patients with false negatives gave positive results within two weeks after cessation of omeprazole or rabeprazole. Consequently, any patients scheduling for UBT were recommended not to take PPIs at least two weeks in advance to avoid false negative results. The time taken for the reversal of false negative results could depend on the time duration of prior PPIs usage. Accordingly, it might take longer in some patients for the test to be positive again.

In conclusion, omeprazole and rabeprazole adversely affected the accuracy of UBT, especially with rabeprazole, which had higher false negative rate. UBT did not seem to be influenced by the administration of rebamipide. It is recommended that PPIs usage should be prohibited for at least two weeks prior to UBT to avoid false negative results.

Acknowledgement
Rabeprazole (pariet®) and rebamipide (mucosta®) were provided by Eisai (Thailand) Marketing Co, Ltd and Thai Otsuka Pharmaceutical Co, Ltd, respectively. The authors have no conflict of interest to report.

References
20. Sakurai K, Osaka T, Yamaki K. Rebamipide induces

